Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 7:20 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 127 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: octreotide acetate Clear all
Completed Phase 1 Interventional

Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer

NCT00006368
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Breast Cancer, Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Lung Cancer, Lymphoma, Melanoma (Skin), Neoplastic Syndrome
Interventions
yttrium Y 90-edotreotide
Radiation
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2003
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated May 1, 2013 · Synced Oct 17, 2026, 7:20 AM EDT
Terminated Phase 2 Interventional Results available

P:II Above-Label Octreotide-LAR With Insufficiently Controlled Carcinoid Syndrome

NCT01886287
View directory record Official record
Conditions
Neuroendocrine Carcinoma
Interventions
Octreotide LAR
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jan 12, 2015 · Synced Oct 17, 2026, 7:20 AM EDT
Completed Phase 4 Interventional Results available

Ultrasound Guided Octreotide LAR Injection in Acromegaly

NCT00552071
View directory record Official record
Conditions
Acromegaly
Interventions
Octreotide LAR 30 MG Injection
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 11, 2018 · Synced Oct 17, 2026, 7:20 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor

NCT00569127
View directory record Official record
Conditions
Colorectal Neuroendocrine Tumor G1, Gastric Neuroendocrine Tumor G1, Neuroendocrine Neoplasm, Neuroendocrine Tumor, Neuroendocrine Tumor G2
Interventions
Bevacizumab, Laboratory Biomarker Analysis, Octreotide Acetate, Recombinant Interferon Alfa-2b
Biological · Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
427 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2027
U.S. locations
493
States / cities
Mobile, Alabama • Fairbanks, Alaska • Fort Smith, Arkansas + 321 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 17, 2026, 7:20 AM EDT
Completed Phase 3 Interventional Results available

A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly

NCT04076462
View directory record Official record
Conditions
Acromegaly
Interventions
CAM2029 (octreotide subcutaneous depot), Matching placebo
Drug
Lead sponsor
Camurus AB
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
12
States / cities
Los Angeles, California • Palo Alto, California • Miami, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 17, 2026, 7:20 AM EDT
Recruiting Phase 3 Interventional

Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET

NCT06784752
View directory record Official record
Conditions
Somatostatin Receptor Positive (SSTR+), Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
Interventions
[177Lu]Lu-DOTA-TATE, Octreotide LAR
Radiation · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years to 100 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
20
States / cities
Scottsdale, Arizona • Fayetteville, Arkansas • Denver, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 17, 2026, 7:20 AM EDT
Terminated Not applicable Interventional Results available

Treatment of Type I Hepatorenal Syndrome (HRS) With Pentoxyfylline

NCT02123576
View directory record Official record
Conditions
Hepatorenal Syndrome
Interventions
Pentoxyfylline, Placebo, AMO Therapy
Drug
Lead sponsor
Patrick Northup, MD
Other
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 29, 2019 · Synced Oct 17, 2026, 7:20 AM EDT
Recruiting Phase 2 Interventional

Prospective Evaluation of 68Ga-DOTATATE PET/CT, Octreotide and F-DOPA PET Imaging in Ectopic Cushing Syndrome

NCT02019706
View directory record Official record
Conditions
ACTH, Cushing's Syndrome
Interventions
DOTATATE PET-CT, F-DOPA PET CT, CT scan, Routine MRI scan, Gated MRI scan, 68Ga-DOTATATE, 18F-DOPA
Radiation · Diagnostic Test · Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 17, 2026, 7:20 AM EDT
Completed Phase 3 Interventional

A Trial to Assess the Long-term Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly

NCT04125836
View directory record Official record
Conditions
Acromegaly
Interventions
CAM2029 (octreotide subcutaneous depot)
Drug
Lead sponsor
Camurus AB
Industry
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
12
States / cities
Los Angeles, California • Palo Alto, California • Miami, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Oct 17, 2026, 7:20 AM EDT
Completed Phase 1 Interventional

Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors

NCT00049023
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Neuroblastoma, Pheochromocytoma, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
90Y-DOTA-tyr3-OCTREOTIDE
Radiation
Lead sponsor
O'Dorisio, M S
Other
Eligibility
2 Years to 25 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jun 21, 2016 · Synced Oct 17, 2026, 7:20 AM EDT
Terminated Phase 3 Interventional

Safety and Biological Activity of C2L-OCT-01 PR in Acromegalic Patients

NCT00642421
View directory record Official record
Conditions
Acromegaly
Interventions
C2L-OCT-01 PR, 10 or 20 mg, C2L-OCT-01 PR, 20 mg
Drug
Lead sponsor
Ambrilia Biopharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
5
States / cities
Los Angeles, California • Stanford, California • Buffalo, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2010 · Synced Oct 17, 2026, 7:20 AM EDT
Terminated Phase 3 Interventional

Octreotide in the Prevention of Diarrhea in Patients Receiving Irinotecan for Metastatic Colon Cancer

NCT00006269
View directory record Official record
Conditions
Colorectal Cancer, Diarrhea
Interventions
irinotecan hydrochloride, octreotide acetate
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
2
States / cities
East Hanover, New Jersey • Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated May 25, 2012 · Synced Oct 17, 2026, 7:20 AM EDT
Completed Phase 1 Interventional

Octreotide and Doxorubicin in Treating Patients With Advanced Cancer

NCT00008073
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
doxorubicin hydrochloride, octreotide acetate
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2002
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 19, 2013 · Synced Oct 17, 2026, 7:20 AM EDT
Completed Phase 2 Interventional Results available

Treatment With Octreotide in Patients With Lymphangioleiomyomatosis

NCT00005906
View directory record Official record
Conditions
Lymphangioleiomyomatosis, Lymphangiomyomas, Pleural Effusions, Ascites
Interventions
Octreotide
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 65 Years · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 30, 2010 · Synced Oct 17, 2026, 7:20 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly

NCT00600886
View directory record Official record
Conditions
Acromegaly
Interventions
Pasireotide, Octreotide
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
14
States / cities
Los Angeles, California • Stanford, California • Gainesville, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 17, 2026, 7:20 AM EDT
Recruiting Phase 1 Interventional

Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors

NCT06441331
View directory record Official record
Conditions
Somatostatin Receptor Positive, NETs, Lymphoma, Solid Tumor, CNS Tumors, Rhabdomyosarcoma, Peripheral Primitive Neuroectodermal Tumor, GIST
Interventions
Lutetium Lu 177-Edotreotide, Amino Acid Solution
Drug · Other
Lead sponsor
ITM Solucin GmbH
Industry
Eligibility
24 Months to 18 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
4
States / cities
San Francisco, California • Cincinnati, Ohio • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 17, 2026, 7:20 AM EDT
Not listed Phase 3 Interventional Results available

Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly

NCT03252353
View directory record Official record
Conditions
Acromegaly
Interventions
octreotide capsules, Matching placebo
Drug
Lead sponsor
Chiasma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
19
States / cities
Los Angeles, California • Palo Alto, California • Aurora, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2020 · Synced Oct 17, 2026, 7:20 AM EDT
Completed Phase 3 Interventional

Octreotide, Tamoxifen, and Chemotherapy in Treating Women With Breast Cancer

NCT00002967
View directory record Official record
Conditions
Breast Cancer
Interventions
cyclophosphamide, doxorubicin hydrochloride, octreotide pamoate, tamoxifen citrate
Drug
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2006
U.S. locations
106
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 87 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2013 · Synced Oct 17, 2026, 7:20 AM EDT
Completed Phase 1 Interventional

Treatment Plan for an Individual Patient With Pasireotide for Hyperinsulinemic Hypoglycemia

NCT03103009
View directory record Official record
Conditions
Hyperinsulinemic Hypoglycemia, Post Gastrointestinal Tract Surgery Hypoglycaemia
Interventions
Pasireotide
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 29, 2021 · Synced Oct 17, 2026, 7:20 AM EDT
Completed Early Phase 1 Interventional

Yttrium-90 DOTA-TOC Intra-arterial (IA) Peptide Receptor Radionuclide Therapy (PRRT) for Neuroendocrine Tumor

NCT03197012
View directory record Official record
Conditions
Neuroendocrine Tumor
Interventions
90Y-DOTA-TOC, 68Ga-DOTA-TOC
Drug
Lead sponsor
Thomas Hope
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 7, 2020 · Synced Oct 17, 2026, 7:20 AM EDT
Completed Phase 2 Interventional Results available

Octreotide for Management of Bronchorrhea in Mechanically Ventilated Patients

NCT02916433
View directory record Official record
Conditions
Octreotide, Sputum
Interventions
Octreotide
Drug
Lead sponsor
Danbury Hospital
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Danbury, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Oct 17, 2026, 7:20 AM EDT
Completed Phase 3 Interventional

Octreotide Acetate in Microspheres in Patients With Diabetic Retinopathy

NCT00131144
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
Octreotide Acetate in Microspheres 20 mg, Octreotide Acetate in Microspheres, Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 70 Years
Enrollment
583 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2005
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 17, 2011 · Synced Oct 17, 2026, 7:20 AM EDT
Completed Phase 4 Interventional

STOP Trial - Sandostatin LAR Depot Trial for the Optimum Prevention of Chemotherapy Induced Diarrhea

NCT00050635
View directory record Official record
Conditions
Neoplasms, Diarrhea
Interventions
Sandostatin LAR Depot
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
34
States / cities
Burbank, California • Concord, California • Fountain Valley, California + 31 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2009 · Synced Oct 17, 2026, 7:20 AM EDT
Terminated Phase 1 Interventional

Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer

NCT00002947
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Childhood Langerhans Cell Histiocytosis, Gastrointestinal Carcinoid Tumor, Head and Neck Cancer, Intraocular Melanoma, Islet Cell Tumor, Kidney Cancer, Lung Cancer, Melanoma (Skin), Neoplastic Syndrome, Neuroendocrine Carcinoma of the Skin, Pheochromocytoma
Interventions
indium In 111 pentetreotide
Radiation
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2004
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 2, 2014 · Synced Oct 17, 2026, 7:20 AM EDT